What's the future of Shengbai pharmaceutical market? Gibel pharmaceutical company will tell you!

After Nanxin pharmaceutical, kechuangban will usher in another pharmaceutical company, jibel In addition to the slow growth of the industry, the company also faces a series of risks, including large dependence on a single product, high customer concentration and low level of R & D investment The stable growth of Shengbai pharmaceutical market is a pharmaceutical high-tech enterprise specialized in the research, development, production and sales of chemical pharmaceutical preparations, Chinese patent medicine preparations and APIs The main product of gibel is likerjun tablet, which is used to prevent and treat leukopenia There are many causes of leukopenia, including bacterial and viral infection, drug factors (such as chemotherapy drugs and antithyroid drugs such as propylthiouracil), connective tissue diseases (systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome, etc.), digestive system diseases (cirrhosis, hepatitis, etc.), and blood system diseases (malignant hematopathy, aplastic anemia, etc.) Blood, megaloblastic anemia, paroxysmal sleep hemoglobinuria, etc.) In recent years, with the change of diet and lifestyle, the pollution of the atmosphere and water, the incidence rate of leukocyte reduction has gradually increased, and more and more attention has been paid by clinicians According to the statistics on the use of drugs in public hospitals in key cities in China made by mienei.com, the sales of Shengbai drugs increased year by year in recent years, from 787 million yuan in 2013 to 1.631 billion yuan in 2018, with a compound growth rate of 15.69% From 2013 to 2018, the sales of whitening promotion drugs in public hospitals in key cities in China are as follows: over 70% of a single product has contributed, and the demand is considerable At present, the company's main products include tablet, capsule and eye drops Among them: tablet products include likerjun tablets, aceclofenac enteric coated tablets, nitrendolol tablets, asarone tablets, etc., capsule products mainly include Yupingfeng capsules and Yiganling capsules, eye drops mainly include gatifloxacin eye drops and lomefloxacin hydrochloride eye drops and other products The prospectus shows that in 2016-2018, the company's revenue was 444 million yuan, 452 million yuan and 485 million yuan respectively; the corresponding net profit was 77.853 million yuan, 77.6105 million yuan and 96.9175 million yuan; in each reporting period, the company's comprehensive gross margin was 84.56%, 85.14% and 86.77% respectively Compared with the gross profit rate of Listed Companies in the same industry, the gross profit rate of the company is slightly higher than the average level of Listed Companies in the same industry Source: prospectus (sorted by Dao Kechuang) The product with the largest contribution of interest rate is likerjun tablet, which is a kind of chemical preparation with the effect of promoting white blood cell proliferation Likerjun tablet can be widely used in the prevention and treatment of leukopenia, thrombocytopenia, aplastic anemia, etc., especially the leukopenia caused by radiotherapy and chemotherapy Leucopenia is also common in the course of radiotherapy and chemotherapy About 70% of cancer patients in China receive radiotherapy One of the side effects of radiotherapy is the impact on the blood system Chemotherapy is one of the most common treatment methods for malignant tumors, and almost all chemotherapy drugs have different degrees of hematopoietic system toxicity, which is the main dose limiting toxicity of tumor chemotherapy The influence of radiotherapy and chemotherapy on leukocytes will limit patients to receive further anti-tumor treatment, and may lead to secondary serious infection, which will reduce the clinical efficacy and the quality of life of patients, so it needs timely prevention and treatment At present, there are many oral leucocyte promoting drugs in clinical use In addition to the exclusive likerjun tablet produced by the company, there are shengbai'an, Fufang Zaofan Pill, qijiaoshengbai capsule, Weixuening, etc Through the experimental study on the efficacy of the above five commonly used oral leukopenia drugs, it is found that the effect of likerjun tablet is the best in improving the number of white blood cells, and likerjun tablet can also improve the red blood cell count, Hb concentration and platelet count According to GLOBOCAN Ou 2018, the number of cancer cases in China reached 4.285 million in 2018, accounting for 23.7% of the global cancer cases It is estimated that the number of cancer cases in China will reach 5.1 million in 2025 and 6.2 million in 2035 The R & D investment is low, and the new products are still being tested The competition in China's pharmaceutical manufacturing industry is more fierce According to the data of the National Bureau of statistics, as of 2017, there are 7532 pharmaceutical manufacturing enterprises above the scale in China, and the industry as a whole is relatively scattered And for most small-scale enterprises, their technical ability is relatively limited, and they can only participate in the market competition through generic products However, there are many large-scale pharmaceutical manufacturing enterprises in the field of generic drugs, so their competitiveness is relatively limited According to the prospectus, the company's R & D investment gradually increased during the reporting period The R & D expenses in 2016-2018 were 16.7509 million yuan, 17.19397 million yuan and 19.5966 million yuan, respectively, but only accounted for 3.77%, 3.79% and 4.04% of the revenue Compared with the listed companies in the same industry, the R & D expense rate of gibel pharmaceutical industry in recent three years is lower than the industry average Jibel pharmaceutical has released new drugs for further research and development The company is researching and developing new products in the common diseases such as depression, malignant tumor, stomach disease, dry eye disease, diabetes, obesity and so on, and transforming them into innovative technologies and achievements Whether the new drug can get the approval document, pass the consistency evaluation, and how the market feedback are unknown As of the date of signing the prospectus, the company's innovative drugs under research include: voltacetin derivatives (antidepressants), docetaxel derivatives (antineoplastics), vonolazan derivatives (antacids), taurochordeoxycholic acid derivatives (cholelithiasis treatment drugs), lifetegrast derivatives (dry eye treatment drugs), sangtonine capsules (hypoglycemic drugs), salt Chloracarine derivatives (weight-loss drugs), etc In conclusion, the single product performance of gibel is outstanding, which is also the biggest focus of this enterprise, but the improvement of tumor treatment technology will have a huge impact on gibel At present, other businesses are not very mature In the long run, the development space is limited Penicillin statement: This article is reprinted by yaozhi.com The copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If you are involved in the work content, copyright and other questions, please contact the official account message We will delete the content at the first time.